SCHEMBL3102803

SCHEMBL3102803

Cc1ccccc1OCCCOc1ccc(CCc2cccc3c2OC(C(=O)O)CN3CCCC(=O)O)cc1

nearest known ligand 0.79

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 19/20 0.79
CYSLTR1 Q9Y271 18/20 0.79
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102830 0.98 CYSLTR2 (0.82) CYSLTR2CYSLTR1
SCHEMBL3105461 0.91 CYSLTR2 (0.83) CYSLTR2CYSLTR1
SCHEMBL3094261 0.91 CYSLTR2 (0.82) CYSLTR2CYSLTR1
SCHEMBL3099568 0.90 CYSLTR2 (0.93) CYSLTR2CYSLTR1
SCHEMBL3094282 0.90 CYSLTR2 (0.86) CYSLTR2CYSLTR1
SCHEMBL3091905 0.89 CYSLTR2 (0.92) CYSLTR2CYSLTR1
SCHEMBL3099323 0.89 CYSLTR2 (0.95) CYSLTR2CYSLTR1
SCHEMBL3081928 0.89 CYSLTR2 (0.82) CYSLTR2CYSLTR1
SCHEMBL3094305 0.89 CYSLTR2 (1.00) CYSLTR2CYSLTR1
SCHEMBL3092350 0.88 CYSLTR2 (0.78) CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661892-B1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-07-24 EP disclosed
US-8318952-B2 Substituted indole derivatives for the treatment of respiratory diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
EP-2481732-A1 Condensed ring compound and use thereof Ono Pharmaceutical Co., Ltd. (JP) 2012-08-01 EP disclosed
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF TAKEUCHI JUN 2010-09-16 US disclosed
US-7763610-B2 Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-20060194797-A1 Condensed ring compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1661892-A1 CONDENSED RING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234368-A1 CONDENSED RING COMPOUND AND USE THEREOF CYSLTR2, CYSLTR1, LTB4R2 CYSLTR2 1/4885CYSLTR1 2/4885PPARG 1563/4885
US-20060194797-A1 Condensed ring compound and use thereof CYSLTR2, CYSLTR1, LTB4R2 CYSLTR2 1/4885CYSLTR1 2/4885PPARG 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.